Anhui Huaren Health Pharmaceutical Co., Ltd. (SHE:301408)
China · Delayed Price · Currency is CNY 14.07
+0.30 (2.18%)
At close: Sep 16, 2026
SHE:301408 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,628 | 7,424 | 4,412 | 6,380 | - | - | |
Market Cap Growth | 2.63% | 68.27% | -30.85% | - | - | - |
Enterprise Value | 5,967 | 8,035 | 4,579 | 6,088 | - | - |
Last Close Price | 14.07 | 18.45 | 10.87 | 15.58 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 25.10 | 38.80 | 32.04 | 55.64 | - | - |
PS Ratio | 0.97 | 1.35 | 0.97 | 1.68 | - | - |
PB Ratio | 2.51 | 3.43 | 2.14 | 3.23 | - | - |
P/TBV Ratio | 6.77 | 9.89 | 4.65 | 5.02 | - | - |
P/FCF Ratio | 9.46 | 10.89 | 10.81 | - | - | - |
P/OCF Ratio | 7.87 | 8.87 | 7.72 | 48.57 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.03 | 1.46 | 1.01 | 1.60 | - | - |
EV/EBITDA Ratio | 7.64 | 18.73 | 16.48 | 33.28 | - | - |
EV/EBIT Ratio | 13.64 | 20.89 | 19.27 | 37.71 | - | - |
EV/FCF Ratio | 10.03 | 11.79 | 11.21 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.57 | 0.63 | 0.60 | 0.65 | 0.81 | 0.76 |
Debt / EBITDA Ratio | 1.63 | 1.88 | 2.31 | 3.47 | 1.94 | 2.23 |
Debt / FCF Ratio | 2.13 | 1.98 | 3.00 | - | 11.03 | 5.59 |
Net Debt / Equity Ratio | 0.12 | 0.17 | 0.10 | -0.03 | 0.30 | 0.40 |
Net Debt / EBITDA Ratio | 0.56 | 0.87 | 0.77 | -0.34 | 1.17 | 1.17 |
Net Debt / FCF Ratio | 0.46 | 0.55 | 0.52 | 0.70 | 4.05 | 2.93 |
Asset Turnover | - | 1.06 | 0.96 | 1.06 | 1.44 | 1.44 |
Inventory Turnover | - | 3.79 | 3.75 | 4.01 | 4.50 | 4.13 |
Quick Ratio | - | 0.59 | 0.69 | 0.97 | 0.73 | 0.69 |
Current Ratio | - | 1.09 | 1.19 | 1.44 | 1.25 | 1.26 |
Return on Equity (ROE) | 11.48% | 10.13% | 7.54% | 8.05% | 18.50% | 9.30% |
Return on Assets (ROA) | - | 4.66% | 3.15% | 2.81% | 6.26% | 4.11% |
Return on Invested Capital (ROIC) | 12.55% | 11.62% | 8.41% | 7.99% | 14.62% | 9.37% |
Return on Capital Employed (ROCE) | - | 13.70% | 9.00% | 6.10% | 18.70% | 9.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.97% | 2.58% | 3.12% | 1.80% | - | - |
FCF Yield | 10.58% | 9.18% | 9.25% | -1.41% | - | - |
Dividend Yield | 0.68% | 0.54% | 0.92% | 0.64% | - | - |
Payout Ratio | 26.73% | 29.65% | 40.66% | 12.81% | 2.57% | 6.23% |
Buyback Yield / Dilution | 1.55% | 1.57% | -2.43% | -15.59% | -3.02% | 2.92% |
Total Shareholder Return | 2.23% | 2.11% | -1.51% | -14.95% | -3.02% | 2.92% |